Streptococcal preparation OK-432 is a bacterial immunopotentiator extensively used in Japan for adjuvant cancer therapy. Using C3H/He mice bearing MH-134 tumour cells, cytokine inductions of tumour necrosis factor-a, interleukin 1~, interleukin 6 and interferon-ywere determined in spleen and tumour tissues by reverse transcriptase-polymerase chain reaction analysis. No significant induction of cytokine mRNA was observed after subcutaneous administration of OK-432 (OK-432, sc) or after intratumoural injection ofIFN-y (IFN-y, it), compared with controls, either in spleen or tumour tissues. In contrast, subcutaneous administration of OK-432 followed by intratumoural OK-432 injection (OK-432, sc-sit) was found to induce some cytokine mRNAs significantly. The mRNA levels of tumour necrosis factor a and interferon-y in spleen tissue and those of interleukin 1~and interferon-y in tumour tissues were significantly elevated in mice with OK-432, sc-rit treatment compared with controls. These results suggest that treatment with OK-432, so--it effectively induced splenic antitumour immunity as well as local immunity against tumour cells.
INTRODUCTION
OK-432 is a penicillin-inactivated and lyophilized preparation of the low-virulence strain Su of Streptococcus pyogenes. The immunomodulatory and potential therapeutic properties of OK-432 as a biological response modifier have been previously described. ' Clinically this preparation has been extensively used in Japan as an adjuvant treatment for patients with lung cancer," oesophageal cancer,' gastrointestinal cancer" and peritoneal carcinomatosis." Immunotherapy with OK-432 has led to improved cancer survival rates when used concomitantly with chemotherapy.v" The precise immune mechanism of action, however, of OK-432 remains unknown
The efficacy of OK-432 has been variably attributed to T cell and natural killer cell activation, macrophage-mediated cytotoxicity, neutrophil activation and multicytokine production." -10 It has been shown that OK-432 is a multicytokine inducer with interleukin 2 (IL-2) playing a major role in natural killer cell activation and interferon-y (IFN-y) production." Recent advances in mRNA detecting systems using reverse transcriptase-polymerase chain reaction (RT-PCR) analysis have enabled us to study the mechanism of the action of OK-432 from the standpoint of the cytokine network. This study was undertaken to analyse the immune mechanism of action of OK-432 using C3H/He mice bearing MH-134 tumour cells.
MATERIALS AND METHODS MATERIALS
OK-432 (Picibanil; Chugai Pharmaceutical Co., Tokyo, Japan) is a lyophilized preparation of group A streptococcus, type 3, Su strain, inactivated with penicillin G. The concentration of OK-432 is expressed in units 28 designated as Klinische Einheit (KE; clinical unit). One KE of OK-432 equals 0.1 mg dried streptococci. Recombinant murine IL-2 was purchased from Shionogi Co. Ltd. (Osaka, Japan), and recombinant murine IFN-y was obtained commercially from PharMingen (San Diego, CA, USA).
ANIMALS
C3H/He mice were obtained from Japan SLC (Hamamatsu, Japan). Male mice, 5 -6 weeks old, were used in all experiments. Mice were maintained in a pathogen-free barrier containment facility on a regulated 12-h light/ dark cycle and were acclimatized for at least 1 week before they were used in any experiment.
CELL CULTURE
Murine MH-134 cells established in our laboratory were cultured in RPMI 1640 supplemented with N-(2-hydroxyethyl)piperazine-N-(2-ethanesulphonic acid), 10% heat-inactivated fetal calf serum, 100 IU/ml of penicillin and 100 ug/rnl of streptomycin at 37°C in a humidified atmosphere with 5% CO 2 • Unfractionated splenocytes, obtained from a pool of three to five mice per experiment, were cultured in duplicate at a cell density of 5 x 10 6 splenocytes per ml in 24-well and 96-well tissue culture plates (Corning, NY, USA). Exogenous murine recombinant IL-2 and/or OK-432 were added to splenocytes cultured in RPMI 1640 supplemented with 10% fetal calf serum at 37°C in a humidified incubator with 5% CO 2 for 40 h, and splenocytes were submitted to RT-PCR analysis. NY, USA) at a concentration of 20 KE/m!' and administered subcutaneously and/or injected intratumouraly in a volume of 0.05 ml (lKE/mouse) to the mice. Intratumoural injection of murine IFN-y was performed in a volume of 0.05 ml (6 x 10 4 IU/mouse).
Mice were inoculated with 1 x 10 7 cells of MH-134 into the right flank (day 0). The mice were then randomized into three groups (eight mice per group) given [i) vehicle containing OK-432 injected subcutaneously on day 5 only (OK-432, sc group), [ii) the subcutaneous OK-432 followed by intratumoural injection of OK-432 on day 7 (OK-432, sc-sit group), or (iii) vehicle containing murine IFN-y injected on day 7 (IFN-y, it group). Tumour tissue and spleen were removed and weighed on days 8, 10 and 12, and submitted to RT-PCR analysis. Tumour volume (mm"l was also calculated by the formula length x width', where the length and width of the tumour were measured using electric calipers.
REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION ANALYSIS
Total RNA was extracted by the acid guanidine phosphate chloroform method described elsewhere." Samples of total RNA (1-5~g) were incubated at 70°C for 15 min in 500 ng of oligonucleotide primer and diethyl pyrocarbonate (DEPCl-treated water in a final volume of 13 ul, then cooled on ice. The cDNA was synthesized by primer extention at 42°C for 55 min using 200 U of Moloney murine leukemia virus (M-MLV) reverse transcriptase (GIBCO-BRL, Gaithersburg, MD, USA) with 20 mM Tris-HCI buffer (pH 8.4) containing 50 mM KCI, 2.5 mM MgCI 2 , 10 mM dithiothreitol and 5 mM each of the four oligonucleotide primers. PCR primers were constructed with the nucleotide sequences of murine tumour necrosis factor-a (TNF-a), interleukin-l~(IL-l~), interleukin-6 (IL-6), IFN-y and~-actin as an internal control. Primer sequences extending over 2 exons were chosen to avoid the amplification of genomic DNA. Conditions for the PCR were 35 cycles at 94°C for 30 s, 64°C for 1 min and 72°C for 1 min. The primer pairs of 5' sense and 3' antisense, designed from the murine cytokine sequence, were as given in Tanabe 0, et al," RT-PCR products were electrophoresed through polyacrylamide gel and the detected bands of the expected size were confirmed by Southern blotting with specific 'l2P-Iabelled oligoprobes synthesized specifically for each RT-PCR product. The reaction products were visualized by subjecting them to electrophoresis in 1.5% agarose gels containing 0.5 mg/ml ethidium bromide.
STATISTICAL ANALYSIS
All measured values are expressed as the mean ± SD. Statistical analysis comprised Student's t-test with P < 0.05 considered to be statistically significant, using Statworks statistical software (Cricket Software Inc., Philadelphia, PA, USA).
RESULTS
No significant differences (P = 0.35) in tumour and spleen weights or volumes were observed during the experimental period.
TNF-a, IL-~and IFN-y mRNA expression were up-regulated after incubation of splenocytes with OK-432. In contrast, IFN-y mRNA was not detected after incubation of splenocytes with IL-2 alone. Expression of these cytokine mRNAs was enhanced after incubation of splenocytes with OK-432 combined with IL-2 ( Fig. 1) .
OK-432 [sc-it] treatment significantly (P < 0.05) increased TNF-a and IFN-y mRNA expression on day 10 in the spleens of tumour-bearing mice, compared with control and OK-432(sc) groups. IFN-y (it) treatment increased IFN-y mRNA expression compared to the control group, but not to a statistically significant extent. Little change in IL-l~and IL-6 mRNA expression was observed in any of the groups (Table 1 ).
In the control group, there were no significant serial changes in cytokine mRNA expression. In contrast, OK-432 (sc--itl treatment significantly increased both TNF-a and IFN-y mRNA expression on day 10 compared with day 8 (P< 0.01). TNF-amRNA expression remained significantly higher compared with day 8, even on day 12. IFN-ymRNA expression on day 12, however, decreased almost to the level of day 8 ( Table 1) .
OK-432 (so-it] treatment significantly (P < 0.05) increased IL-l~and IFN-y mRNA expression on day 10 in tumour tissue of tumour-bearing mice, compared with control, OK-432 (sc) and IFN-y (it) groups. No significant changes in TNF-a or IL-6 mRNA expression were observed in any ofthe groups ( Table 2 ).
In the control group, there were no significant serial changes in cytokine mRNA expression. In contrast, OK-432 (sc-It) treatment significantly increased both IL-l~arid IFN-y mRNA expression on day 10 compared with day 8 (P < 0.05). IL-l~mRNA expression on day 12 was further increased and its level remained significantly higher than that on day 8 (P < 0.01). In contrast, IFN-y mRNA expression on day 12 returned towards its level on day 8 ( Table 2) . 
TABLE 1

Effects of OK-432 and interferon-y(IFN-y) treatment on the expression of mRNA of various cytokines in the spleens of mice bearing tumour cells
DISCUSSION
Streptococcal preparation OK-432 has been used for the clinical treatment of cancer patients for more than 20 years in Japan. Systemic administration of OK-432 combined with chemotherapy has been shown to enhance the host immune response in patients with lung cancer" and gastrointestinal cancers. Repeated local and direct administration of OK-432 into the tumour site, as in the administration into the peritoneal cavity for malignant ascites." or endoscopic injection into gastrointestinal cancer: has proved effective in initiating a local immune response against the cancer.
The efficacy of OK-432 has been variably attributed to T-cell and naturalkiller-cell activation, macrophage-mediated cytotoxicity and multicytokine production.t" " It has been shown that OK-432 is a multicytokine inducer with IL-2 playing a major role in natural-killer-cell activation and IFN-y production." The present results also demonstrated that OK-432-derived cytokine mRNA expression of TNF-a, IL-IP and IFN-y by splenocytes were significantly augmented when cultured with IL-2. When mouse splenocytes were activated with IL-2 alone, IFN-y mRNA expression was not detected (Fig. 1) . These results suggest that OK-432 elicited cytokine responses that were partially but not completely IL-2 dependent. It has been reported that splenocytes cultured with OK-432 acquired direct cytotoxicity to autologous as well as allogenic tumour cells, and were expressed OK-432activated killer spleen cells." As shown in Fig. 1 , when splenocytes were cultured with OK-432, IFN-y mRNA was clearly expressed. This finding also indicated the potential of splenocytes as effector cells against tumours. In addition, the present results demonstrate that OK-432 (sc+it) treatment significantly increased IFN-y mRNA expression on day 10 both in spleen and tumour tissue compared with the control and OK-432 (sc) groups (Tables 1 and 2) . These results suggested that priming by OK-432 alone did not increase IFN-ymRNA expression significantly.
TABLE 2
Effects of OK-432 and interferon-y(IFN-11 treatments on the expression of mRNA of various cytokines in the tumour tissues of mice bearing tumour cells
The efficacy of adoptive immunotherapy using lymphocytes from an HLA-matched sibling and OK-432 as an antigen has also been reported.' After the donor had been immunized by intradermal administration of OK-432, OK-432-reactive lymphocytes were induced in vitro and transferred to the patient intravenously." Bearing in mind our results, one of the effector mechanisms of therapeutic benefit might be cytokine release from the transferred OK-432-reactive lymphocytes.
Previous reports demonstrated that patients with advanced cancer had a significant depression of OK-432 -inducible cytokine production (TNF-a, IL-lP, IFN-y) by peripheral blood mononuclear cells at baseline." A phase-I B study of OK-432 has been conducted in 48 patients with cancer at the University of Pittsburgh Cancer Institute, Pennsylvania, USA. 17 This study evaluated the immunomodulatory activity of OK-432, administered intradermally twice weekly for 3 months. It demonstrated that the decreased production of TNF-a, IL-lp and IFN-y by 33 peripheral blood mononuclear cells associated with advanced cancer could be mitigated by treatment with OK-432. 17 The present findings that OK-432 (sc--itl treatment increased expression of TNF-a mRNA in spleen, IL-IP mRNA in tumour tissue, and IFN-y mRNA both in spleen and in tumour tissues in mice are consistent with these reports.
Interleukin-12 (IL-12) is a recently described cytokine that is a principal regulator of cytokines and T-cell subsets; it is produced by phagocytic cells in response to several Gram-positive and Gram-negative bacteria, and to lipopolysaccharide.P:" IL-12 enhances IFN-y production and diminishes IL-4 production by polarizing the T helper cell response towards a T-helper-cell-ldominant state." The effects ofIL-12 on T and natural killer cells includes enhanced proliferation and cytolytic activity," as well as induction of IFN_y.22-25 IL-12 has potent in vivo antitumour and antimetastatic effects against murine tumours mediated through CD8+ T cells and T-cell production of IFN _yo 2".27 OK-432 has recently been reported to be a potent inducer of IL-12 and T Helper Cell I dominant state." OK-432 induced macrophage IL-12 in an in vivo model and in human peripheral blood mononuclear cells in vitro. Most of the OK-432-induced IL-12 has been reported to be derived from macrophages, indicating another critical role for antigenpresenting cells initiating cellular immune responses. It has also been demonstrated that substantial IFN-y was only produced from mixtures of CD4+ or CD8+ T cells with macrophages, and could not be induced by substituting exogenous IL-12. 2R This suggests that OK-432-driven endogenous IL-12 is indispensable in inducing subsequent IFN-y production, and implies that co-operative interactions between antigen-presenting cells and T cells is required for IFN-y induction.
OK-432 also induced an increase in IFN-y in the serum in OK-432 primed mouse in vivo. Given the potent antitumour effect of IL-12 against murine tumours," it is quite plausible that OK-432 exerts its antitumour activity primarily through the production of IL-12 and IFN-y.
Although IFN-y has been reported to stimulate IL-12 production and may be required for its initial induction.i'v":" the present results demonstrate that IFN-y (it) treatment does not increase IFN-y mRNA expression either in spleen or in tumour tissues. Conceivably, antigen-presenting cells in spleen and in tumour tissues had not been primed by exogenous IFN-y injection. In addition, IFN-y (it) treatment did not increase mRNA expression ofTNF-a and IL-lp (Tables  1 and 2) , released from activated macrophages, reflecting the fact that exogenous IFN-y injection into tumour site did not activate antigen-presenting cells.
The effect of cytokine neutralizing antibodies on IFN-y production by OK-432activated splenocytes has been studied;" Anti-IL-12 antibody markedly inhibited IFN-y production by OK-432-activated splenocytes just as it completely neutralizes endogenous IL-12. Anti-IL-2 antibody, anti-TNF-a antibody and anti-IL-l antibody inhibited about half ofIFN-y production. In contrast, anti-IL-6 antibody had no effect on IFN-y or IL-12 production;" which is consistent with the present findings that expression of IL-6 mRNA did not increase with OK-432 (sc-rit] or OK-432 (sc) treatment. An analysis of the time-course of cytokine mRNA expression by OK-432 provides important insights into the manner by which the cytokine network orchestrates and regulates IFN-y production. Although IL-12 mRNA was not measured in the present study, it is possible that OK-432driven endogenous IFN-yproduction by CD4+ and CD8+ T cells (and possibly NK cells) was dependent on TNF-a/IL-lpIIL-12; this speculation is consistent with previous reports." IFN-y is reported to inhibit the growth of tumours of various types.":" Endogenous IFN-y produced in response to certain immunopotentiators may also exert other direct and indirect effects on tumours and the local immune environment including upregulation of cell surface major histocompatibility antigens, adhesion molecules and apoptosis inducers such as Fas and TNF receptors.i":" IFN-y has also been shown to induce a cascade of other inflammatory mediators such as CXC chemokine IP_l0. 26 It is, therefore, possible that OK-432 exerts its antitumour activity primarily through the production of IFN-y, and local administration ofOK-432 as an antigen might represent a new strategy for cancer therapy. Nevertheless, the increase in IFN-y mRNA expression in spleen and tumour tissues was observed only on day 10, and its expression returned to basal levels on day 12 (Tables 1 and 2) . Further studies to investigate whether OK-432 might be effective as an antigen in cancer therapy are needed.
